CBLL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

6 Analyst Rating

Wall Street analysts forecast CBLL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBLL is 22.40 USD with a low forecast of 17.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

17.00

Averages

22.40

High

30.00

Current: 0.000

Low

17.00

Averages

22.40

High

30.00

Canaccord

Buy

maintain

$29 -> $30

2025-12-17

Reason

Canaccord

Price Target

$29 -> $30

2025-12-17

maintain

Buy

Reason

Canaccord raised the firm's price target on Ceribell to $30 from $29 and keeps a Buy rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.

TD Cowen

Buy

maintain

$20 -> $29

2025-12-09

Reason

TD Cowen

Price Target

$20 -> $29

2025-12-09

maintain

Buy

Reason

TD Cowen raised the firm's price target on Ceribell to $29 from $20 and keeps a Buy rating on the shares after the company announced that it has received FDA 510(k) clearance for its delirium monitoring solution. The clearance, making its system the first and only U.S.-approved device for delirium screening and monitoring, comes months ahead of expectations and will significantly expand the company's total addressable market for adult seizure detection, the analyst tells investors.

JPMorgan

Overweight

Buy

downgrade

$21 -> $17

2025-11-05

Reason

JPMorgan

Price Target

$21 -> $17

2025-11-05

downgrade

Overweight

Buy

Reason

JPMorgan lowered the firm's price target on Ceribell to $17 from $21 and keeps an Overweight rating on the shares. The company reported another good "beat-and-raise" with tailwinds heading into 2026, the analyst tells investors in a research note.

TD Cowen

Buy

downgrade

$36 -> $20

2025-11-05

Reason

TD Cowen

Price Target

$36 -> $20

2025-11-05

downgrade

Buy

Reason

TD Cowen lowered the firm's price target on Ceribell to $20 from $36 and keeps a Buy rating on the shares. The firm updated its model following a solid quarter and guidance that reflects continued adoption.

Raymond James

Jayson Bedford

Strong Buy

initiated

$19

2025-10-20

Reason

Raymond James

Jayson Bedford

Price Target

$19

2025-10-20

initiated

Strong Buy

Reason

Raymond James analyst Jayson Bedford initiated coverage of Ceribell with a Strong Buy rating and $19 price target. Ceribell is pioneering the rapid EEG market with differentiated technology that improves outcomes for patients and providers, says the analyst, who sees "consistent execution" as "disconnected from stock price performance" with shares down 51% year-to-date. The firm says its rating is "not a call" on Q3 results, but its belief that the valuation does not match the financial profile and "gives little credit for current (and pipeline) opportunities."

BTIG

Marie Thibault

initiated

$30

2025-06-24

Reason

BTIG

Marie Thibault

Price Target

$30

2025-06-24

initiated

Reason

BTIG analyst Marie Thibault initiated coverage of Ceribell with a Buy rating and $30 price target. "Ceribell has developed the point-of-care Ceribell System for rapid electroencephalogram monitoring, the analyst tells investors in a research note. The firm says the system uses the company's proprietary artificial intelligence-driven Clarity algorithm, the first to receive an on-label indication for the diagnosis of electrographic status epilepticus, defined as a seizure lasting continuously for over five minutes. While still in the early stages of commercialization, Ceribell is "poised for growth," contends BTIG.

Valuation Metrics

The current forward P/E ratio for Ceribell Inc (CBLL.O) is -14.04, compared to its 5-year average forward P/E of -12.14. For a more detailed relative valuation and DCF analysis to assess Ceribell Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.14

Current PE

-14.04

Overvalued PE

-6.80

Undervalued PE

-17.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-11.77

Current EV/EBITDA

-10.84

Overvalued EV/EBITDA

-3.28

Undervalued EV/EBITDA

-20.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

7.41

Current PS

7.45

Overvalued PS

10.75

Undervalued PS

4.06

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CBLL News & Events

Events Timeline

No data

News

9.0

01-05NASDAQ.COM

CeriBell (CBLL) Receives FDA Breakthrough Device Designation for Stroke Detection Monitor

1.0

2025-12-30Globenewswire

CeriBell CEO Jane Chao to Present at 2026 J.P. Morgan Healthcare Conference

7.5

2025-12-12PRnewswire

Ventripoint Partners with Nisg̱a'a to Advance Cardiac Imaging in Remote Communities

People Also Watch

Frequently Asked Questions

What is Ceribell Inc (CBLL) stock price today?

The current price of CBLL is 23.33 USD — it has increased 1.13 % in the last trading day.

What is Ceribell Inc (CBLL)'s business?

CeriBell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining highly portable and rapidly deployable hardware with artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared (510(k)) for indicating suspected seizure activity and utilized in intensive care units and emergency rooms across the United States. Clarity, its machine learning algorithm, continuously interprets a patient’s EEG waveforms and displays actionable insights regarding seizure activity on the recorder. Its EEG portal is a cloud-based portal that enables real-time remote access to a patient’s EEG data.

What is the price predicton of CBLL Stock?

What is Ceribell Inc (CBLL)'s revenue for the last quarter?

Ceribell Inc revenue for the last quarter amounts to 22.59M USD, increased 31.37 % YoY.

What is Ceribell Inc (CBLL)'s earnings per share (EPS) for the last quarter?

Ceribell Inc. EPS for the last quarter amounts to -0.37 USD, increased 19.35 % YoY.

What changes have occurred in the market's expectations for Ceribell Inc (CBLL)'s fundamentals?

The market is revising Upward the revenue expectations for CeriBell, Inc. (CBLL) for FY2025, with the revenue forecasts being adjusted by 1.52% over the past three months. During the same period, the stock price has changed by 95.23%.

How many employees does Ceribell Inc (CBLL). have?

Ceribell Inc (CBLL) has 281 emplpoyees as of January 10 2026.

What is Ceribell Inc (CBLL) market cap?

Today CBLL has the market capitalization of 865.44M USD.